Search Results

Celularity Inc. announced expected net sales of its biomaterial products and biobanking businesses for the first quarter 2024 and the full year 2024, respectively, and reiterated its previously disclosed advanced biomaterial product commercial and development pipeline.

Celularity Inc. today announced that its expected net sales for the first quarter of 2024 are trending ahead of the expectations it announced in February for its advanced biomaterial products and biobanking businesses.

Celularity Inc. (Nasdaq: CELU) (“Celularity”) today announced that its abstract entitled “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” was accepted by the Orthopedic Research Society (ORS) Tendon Conference, which will be held from May 30 - June 1, 2024 at the Mayo Clinic in Rochester, MN.

Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today confirmed that it has entered into an exclusive U.S. strategic commercialization agreement with BioCellgraft, Inc. (“BioCellgraft”) under which Celularity will manufacture advanced biomaterial products for BioCellgraft which BioCellgraft will distribute in the United States for use in multiple dental/oral healthcare applications.

On January 11th, trailblazing medical technology company Xenco Medical unveiled its convergent technology bridging Digital Health and Biomaterials by showcasing its TrabeculeX Continuum™ at the 2024 Consumer Electronics Show in Las Vegas, Nevada.

Celularity Inc. announced that its Halal Certified biomaterial products have been classified by the Saudi Food and Drug Authority as “Minimally Manipulated Biological Products” for importation license purposes in the Kingdom of Saudi Arabia.

Biocoat Incorporated , a specialty manufacturer of hydrophilic biomaterial coatings and coating equipment for medical devices, announced today that it has acquired Chempilots, a European provider of specialty polymers and production services to the medical device industry.

Celularity Inc., a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced that it will present data on its proprietary extracellular matrices at ICBST23, the International Conference on Biomaterials Science and Tissue Engineering, to be held on 24-26 July in Osaka, Japan.

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today an oral and poster presentation at the upcoming 2023 Annual Meeting Society for Biomaterials (“SFB”), which will be held April 19th – 22nd in San Diego, CA.